Infectious Disease Outpatient Follow-Up Note

Date: [Date]

Patient: [Patient name or identifier]

Visit Type: [in-person / telehealth]

Visit Context: [post-hospital follow-up / OPAT monitoring / end-of-therapy evaluation / recurrent infection evaluation / other: specify]

Interval History

[Reason for visit summarizing primary infection and therapy decision] (Begin with a 1–2 line statement that clearly identifies the infection and the key decision point for this visit.)

[Infection context: syndrome/site, organism and susceptibilities, relevant dates, current day of therapy, target duration/end date] (For first post-discharge follow-up, use 4–6 concise lines; for subsequent follow-ups, provide a 1–2 line anchor refresh.)

• Interval course: [Symptom trajectory since last visit] — [improved / stable / worsened] (Include new events such as ED visits, procedures, imaging, or medication changes. Note any persistent or new focal symptoms suggesting incomplete source control or metastatic infection.)
• Antimicrobial therapy review:
  • Current regimen: [drug, dose, route, frequency]; [start date]; [planned stop date or total duration anchored to event]
  • Adherence: [missed doses and reasons, infusion schedule reliability]
  • Tolerance: [GI symptoms, rash, agent-specific toxicities, symptomatic lab abnormalities]
  • Vascular access: [line type]; [site findings] (Include only for IV therapy.)
• Targeted ROS: [Additional symptoms relevant to therapy decisions, drug toxicity, or relapse] (Include only if not already captured above.)

Objective

• Vitals: [Vital signs] (Include if measured or clinically relevant.)
• Exam: [Pertinent findings by system, emphasizing infection-relevant areas and target site exam with pertinent positives and negatives]
• Data Reviewed:
  • Labs: [Inflammatory markers, renal/hepatic function, drug levels with dates and trends]
  • Microbiology: [Culture results, susceptibilities, clearance dates]
  • Imaging: [Study type and date] — [key findings affecting decisions]
  • External records: [Home infusion notes, SNF MAR, outside labs with source and date] (Include only if reviewed.)
• Missing safety-critical data: [Data missing and why] — [plan to obtain and interim safety instructions] (Include only if applicable; e.g., missing renal function for nephrotoxic agent.)

Assessment & Plan

1. [Primary infection under treatment]

   Assessment: [Clinical status: improving / stable / worsening], supported by [interval symptoms, exam findings, lab trends, imaging evolution, source control status].

   Plan: [Therapy decision: continue / stop / extend / change] — [Clinical rationale linking symptoms, objective data, and source control].

   • Regimen: [drug, dose, route, frequency]; [start date]; [planned stop date or total duration]
   • Monitoring: [specific labs and frequency]; [who reviews]; [thresholds for action]
   • Additional workup: [needed diagnostics, imaging, or consultations with timing] (Include only if applicable.)
   • Source control: [actions needed or confirmation of adequacy] (Include only if applicable.)
   • Return precautions: [symptoms warranting urgent evaluation]

   (When stopping therapy: document evidence of response, source control adequacy, final stop date, line removal plan, and relapse monitoring. When extending therapy: document why expected duration is insufficient, revised end date, and what determines the next decision.)

2. [Additional problem: OPAT/line issue, antimicrobial toxicity, or recurrence prevention] (Include only if a distinct clinical decision is required at this visit.)

   Assessment: [Problem description and severity]

   Plan: [Interventions, monitoring, or referrals]

Follow-Up

• Next appointment: [timeframe and format]
• Lab schedule: [tests and frequency]; [who reviews and how results are communicated]
• Care coordination: [communications with PCP, specialists, home infusion, or pharmacy] (Include only if performed.)